查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1490928

流感药物市场 - 药物类型、流感类型、年龄层、给药途径、类型、药物、配销通路、全球预测

Influenza Medications Market - Drug Type, Influenza Type, Age Group, Route of Administration, Type, Medication, Distribution Channel, Global Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 267 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于全球流感感染发生率不断增加，预计 2024 年至 2032 年间流感药物市场规模的复合年增长率为 2.9%。根据世界卫生组织的数据，每年约有 10 亿例季节性流感病例，其中 300-500 万例被归类为重症。随着全球人口的不断增长，流感病毒的传播变得越来越普遍，进一步需要有效的药物来控制和治疗这种疾病。医疗保健专业人员和患者对流感早期诊断和治疗重要性的认识不断提高，这将推动产品需求。

近年来，人们不断努力开发疗效增强、副作用较少的新型抗病毒药物，并引入创新的给药方法，例如静脉注射和鼻内製剂。针对不同流感病毒株的疫苗的开发以及政府和医疗机构为降低流感感染的发生率和严重程度而采取的疫苗接种活动也将刺激市场成长。

流感药物产业分为药物类型、流感类型、年龄层、给药途径、类型、用药、配销通路和区域。

根据给药途径，静脉注射领域的市场份额预计在 2024 年至 2032 年期间将实现 1.3% 的增长率，因为它能够将药物直接输送到血液中，同时确保药物的快速有效吸收。这种给药途径在严重流感感染或口服药物不可行的情况下特别有利，因为它可以确保立即和有针对性的治疗。静脉注射也使医疗保健专业人员能够密切监测患者对药物的反应，并根据需要调整剂量，以提高治疗效果并降低併发症的风险。

根据配销通路，到 2032 年，线上药局领域的流感药物市场将以 4.5% 的复合年增长率成长，这得益于其便利性、可及性和成本效益。随着医疗保健需求越来越依赖数位平台，消费者开始转向线上药局，在家中舒适地购买流感药物。线上药局能够比较价格、取得多种产品并在短时间内接受送货上门的服务，这使得线上药局成为寻求及时治疗流感症状的个人的一个有吸引力的选择。

亚太地区流感药物产业预计将产生利润丰厚的机会，并在 2024 年至 2032 年期间以 3.6% 的复合年增长率扩张。这可以归因于各国政府和医疗机构为应对流感疫情而提高的认识和采取的积极措施，特别是在中国和印度等人口稠密的国家。医疗保健基础设施发展的兴起，加上医疗技术和药品製造能力的进步，将进一步推动该地区的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 流感盛行率增加
      • 提高对流感药物的认识与采用
      • 增加与流感药物相关的研发活动
    • 产业陷阱与挑战
      • 与抗病毒药物相关的副作用
      • 与药物开发相关的高成本
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物类型，2018 - 2032

  • 主要趋势
  • 抗病毒药物
    • 单一抗病毒药物
    • 联合抗病毒药物
  • 抗组织胺药
  • 止痛药
  • 退烧药

第 6 章：市场估计与预测：按流感类型，2018 年 - 2032 年

  • 主要趋势
  • 甲型流感
  • 乙型流感

第 7 章：市场估计与预测：按年龄划分，2018 年 - 2032 年

  • 主要趋势
  • 成年人
  • 儿科
  • 老年科

第 8 章：市场估计与预测：按管理途径，2018 - 2032 年

  • 主要趋势
  • 口服
  • 吸入
  • 静脉

第 9 章：市场估计与预测：按类型，2018 - 2032

  • 主要趋势
  • 品牌化
  • 通用的

第 10 章：市场估计与预测：按药物分类，2018 - 2032 年

  • 主要趋势
  • 处方
  • 场外交易

第 11 章：市场估计与预测：按配销通路划分，2018 年 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 12 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 13 章：公司简介

  • AstraZeneca plc
  • BioCryst Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Lupin
  • NATCO Pharma Limited
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
简介目录
Product Code: 8695

Influenza Medications Market size is projected to witness 2.9% CAGR between 2024 and 2032, owing to increasing incidences of influenza infections worldwide. As per WHO, every year, approximately 1 billion cases of seasonal influenza occur, with 3-5 million instances categorized as severe illness. With the expanding global population, the spread of influenza viruses is becoming more prevalent, further imposing the need for effective medications to manage and treat the illness. The rising awareness among healthcare professionals and patients about the importance of early diagnosis and treatment of influenza will fuel the product demand.

Lately, there have been continuous efforts to develop new antiviral drugs with enhanced efficacy and fewer side effects, along with the introduction of innovative drug delivery methods, such as intravenous and intranasal formulations. The development of vaccines targeting different strains of influenza viruses and the adoption of vaccination campaigns by governments and healthcare organizations for reducing the incidence and severity of influenza infections will also stimulate the market growth.

The influenza medications industry is classified into drug type, influenza type, age group, route of administration, type, medication, distribution channel and region.

Based on route of administration, the market share from the intravenous segment is slated to record 1.3% growth rate during 2024-2032, due to its ability to deliver medications directly into the bloodstream while ensuring rapid and efficient absorption of the drug. This route of administration is particularly advantageous in cases of severe influenza infections or when oral medications are not feasible as it ensures immediate and targeted treatment. IV administration also enables healthcare professionals to closely monitor the patient's response to the medication and adjust the dosage as needed for enhancing treatment outcomes and reducing the risk of complications.

As per distribution channel, the influenza medications market from the online pharmacies segment will grow at 4.5% CAGR through 2032, backed by their convenience, accessibility, and cost-effectiveness. With the increasing reliance on digital platforms for healthcare needs, consumers are turning to online pharmacies to purchase influenza medications from the comfort of their homes. The ability to compare prices, access a wide range of products, and receive doorstep delivery within a short timeframe makes online pharmacies an attractive option for individuals seeking timely treatment for influenza symptoms.

Asia Pacific influenza medications industry is expected to generate lucrative opportunities and expand at a 3.6% CAGR from 2024-2032. This can be attributed to the increasing awareness and proactive measures taken by governments and healthcare organizations to combat influenza outbreaks, particularly in densely populated countries, such as China and India. The rise in healthcare infrastructure development, coupled with advancements in medical technology and drug manufacturing capabilities will further propel the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of influenza
      • 3.2.1.2 Rising awareness and adoption of influenza medications
      • 3.2.1.3 Increasing research and development activities related to influenza drugs
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Side effects associated with antiviral drugs
      • 3.2.2.2 High cost associated with drug development
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Antiviral drugs
    • 5.2.1 Single antiviral drugs
    • 5.2.2 Combination antiviral drugs
  • 5.3 Antihistamines
  • 5.4 Analgesics
  • 5.5 Antipyretics

Chapter 6 Market Estimates and Forecast, By Influenza Type, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Influenza A
  • 6.3 Influenza B

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adults
  • 7.3 Pediatric
  • 7.4 Geriatric

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Oral
  • 8.3 Inhaled
  • 8.4 Intravenous

Chapter 9 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Branded
  • 9.3 Generic

Chapter 10 Market Estimates and Forecast, By Medication, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 Prescription
  • 10.3 OTC

Chapter 11 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 11.1 Key trends
  • 11.2 Hospital pharmacies
  • 11.3 Retail pharmacies
  • 11.4 Online pharmacies

Chapter 12 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 12.1 Key trends
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 France
    • 12.3.4 Spain
    • 12.3.5 Italy
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 China
    • 12.4.2 Japan
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 Rest of Asia Pacific
  • 12.5 Latin America
    • 12.5.1 Brazil
    • 12.5.2 Mexico
    • 12.5.3 Rest of Latin America
  • 12.6 Middle East and Africa
    • 12.6.1 South Africa
    • 12.6.2 Saudi Arabia
    • 12.6.3 Rest of Middle East and Africa

Chapter 13 Company Profiles

  • 13.1 AstraZeneca plc
  • 13.2 BioCryst Pharmaceuticals, Inc.
  • 13.3 Daiichi Sankyo Company
  • 13.4 F. Hoffmann-La Roche AG
  • 13.5 GlaxoSmithKline plc
  • 13.6 Lupin
  • 13.7 NATCO Pharma Limited
  • 13.8 Novartis AG
  • 13.9 Sanofi
  • 13.10 Teva Pharmaceutical Industries Ltd.